Saturday July 04 2009 | Biotechnology feed | All feeds
|
|
Saturday July 04 2009 | Biotechnology feed | All feeds
|
|
|
Female arousal disorder More American women (43%; about 40 million) than men (31%) experience some form of sexual disorder. Female sexual dysfunction represents a family of conditions that have few pharmacological therapies. Of interest, and in contrast to males, the distribution of female dysfunctions is fairly even among women ranging from 18 to 59 years of age. Approximately 20% of women with female sexual dysfunction suffer arousal disorder characterized by either a failure of vaginal engorgement/lubrication or an altered appraisal of arousal, and it has been suggested that treatments of female arousal disorder represent a market of similar size to that of erectile dysfunction. In light of this major unmet need LeadDiscovery has recently produced a report entitled "Male and female sexual dysfunction: Blockbuster indication for multiple pharmacological targets" (click here to access). This report analyzes the therapeutic and pharmaceutical potential of established and emerging targets for sexual dysfunctions and concludes that the adrenoceptor represents an excellent target for both erectile dysfunction and female arousal disorder. This conclusion is in part supported by a recent University of Texas trial. This study examined the effects of the nitric oxide-precursor L-arginine with or without the alpha 2-blocker yohimbine on subjective and physiological sexual arousal in postmenopausal women with female sexual arousal disorder. The combined oral administration of L-arginine glutamate and yohimbine substantially increased vaginal pulse amplitude (a measure of blood flow, which is in turn related to lubrication) responses to the erotic film. Subjective reports of sexual arousal were significantly increased with exposure to the erotic stimuli, however despite the increase in blood flow associated with drug treatment a corresponding increase in sexual arousal was not reported. This supports the use of nitric oxide donors and adrenoceptor antagonists to improve lubrication and further studies are awaited to determine whether this can translate to increased arousal in patient sub-groups or in the context of a non-laboratory setting. Entry date October, 2002 Adapted from Meston et al, Arch Sex Behav 2002 Aug;31(4):323-32
Interested in collaborating with this group? Contact leaddiscovery@bioportfolio.co.uk LeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
|
